Pharnext to Showcase PLEOTHERAPY™ R&D Platform at the 8th Annual Global Orphan Drug Conference
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced that Rodolphe Hajj, Ph.D., the Company’s Chief Pharmacology Officer, will present at the 8th Annual Global Orphan Drug Conference.
The presentation will take place as follows:
- Date & Time: Wednesday April 25th at 4:40 pm EST
- Title: “Next generation drug repurposing using network pharmacology to develop new therapeutic entities for rare diseases”
- Venue: Gaylord National Harbor Hotel, Oxon Hill, MD, U.S.
Pharnext’s team will also attend the 2018 American Academy of Neurology Annual Meeting as a first-time exhibitor (booth 908). The meeting will take place on April 21-27, 2018 in Los Angeles, CA, U.S.
If you are interested in meeting the Pharnext management team during these events, please send an email to email@example.com .
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease 1A type and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big data genomics and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
For more information, visit www.pharnext.com .
Chief Commercial Officer
+33 (0)1 41 09 22 3030
Investor Relations (Europe)
MC Services AG
+49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
+1 212 362 1200
Financial Communication (France)
+33 (0)1 56 88 11 15
Media Relations (Europe)
+33 (0)1 44 54 36 66
Media Relations (U.S.)
+1 212 223 0561
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FCF-FISHERY26.5.2018 20:04 | pressemeddelelse
FCF: Greenpeace Allegations Unfair and Deceptive
IBC25.5.2018 20:22 | pressemeddelelse
NBC Universal, Havas Group and Endemol Shine Discuss a Future with AI, Blockchain and VR at IBC2018
THE-FRENCH-PAVILION25.5.2018 11:28 | pressemeddelelse
Pavilion of France at the 16th International Architecture Exhibition – La Biennale di Venezia
SIA25.5.2018 10:32 | pressemeddelelse
SIA Acquires Card Processing Businesses in Central and Southeastern Europe from First Data
PA-WESTINGHOUSE-ELECTRIC25.5.2018 08:02 | pressemeddelelse
Westinghouse Accident Tolerant Fuel Development Moves Forward with Cooperation Agreement with ENUSA
BRIC-HOLDING25.5.2018 08:02 | pressemeddelelse
BRIC HOLDING Offers Aimedis – ICO: Germany’s Leading eHealth Platform Goes Public
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum